IMGN has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
IMGN has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Immunogen has the Growth Rank of 2.
GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:
1. 5-year revenue growth rate, the higher, the better.GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.
Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.
For the Biotechnology subindustry, Immunogen's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Immunogen's Growth Rank distribution charts can be found below:
* The bar in red indicates where Immunogen's Growth Rank falls into.
Thank you for viewing the detailed overview of Immunogen's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.
Theresa Wingrove | officer: VP of Regulatory Affairs | IMMUNOGEN, INC., 830 WINTER STREET, WALTHAM MA 02451 |
Renee Lentini | officer: V.P.-Fin., Prin. Acctg. Off. | 830 WINTER STREET, WALTHAM MA 02451 |
Stacy Ann Coen | officer: Chief Business Officer | 11 RUSH POND RD, LAKEVILLE MA 02347 |
Kristine Peterson | director | AMARIN CORPORATION, MYSTIC PACKER BLDG., 12 ROOSEVELT AVENUE, MYSTIC CT 06355 |
Lauren White | officer: SVP, CFO and PFO | C4 THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 200, WATERTOWN MA 02472 |
Mark J Enyedy | director, officer: Chief Executive Officer | C/O FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO CA 92121 |
Isabel Kalofonos | officer: SVP & CHIEF COMMERCIAL OFFICER | C/O IMMUNOGEN, INC., 830 WINTER STREET, WALTHAM MA 02451 |
Michael Vasconcelles | officer: EVP R&D & MEDICAL AFFAIRS | C/O UNUM THERAPEUTICS, 200 CAMBRIDGEPARK DR., STE. 3100, CAMBRIDGE MA 02140 |
Daniel Char | officer: SVP & CHIEF LEGAL OFFICER | C/O EVELO BIOSCIENCES, INC., 620 MEMORIAL DRIVE, SUITE 200, CAMBRIDGE MA 02139 |
Kristen Harrington-smith | officer: SVP & Chief Commercial Officer | C/O IMMUNOGEN, INC., 830 WINTER STREET, WALTHAM MA 02451 |
Tracey L Mccain | director | C/O BLUEPRINTS MEDICINES CORPORATION, 38 SIDNEY STREET, SUITE 200, CAMBRIDGE MA 02139 |
Helen M. Thackray | director | C/O GLYCOMIMETICS, INC., 401 PROFESSIONAL DRIVE, SUITE 250, GAITHERSBURG MD 20879 |
David G Foster | officer: V.P.-Fin., Prin. Acctg. Off. | C/O IMMUNOGEN, INC., 830 WINTER STREET, WALTHAM MA 02451 |
Susan Altschuller | officer: SVP and CFO | 45 TENNYSON ST., SOMERVILLE MA 02145 |
Craig Barrows | officer: Vice-President,General Counsel | C/O IMMUNOGEN, INC., 830 WINTER STREET, WALTHAM MA 02451 |
From GuruFocus
By Business Wire • 07-31-2023
By Business Wire • 11-02-2023
By PRNewswire • 12-09-2023
By Business Wire • 09-05-2023
By Business Wire • 08-28-2023
By Business Wire • 09-18-2023
By Business Wire • 01-03-2024
By Business Wire Business Wire • 05-24-2023
By Business Wire • 11-01-2023
By Business Wire • 12-01-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.